Glaukos COO Calcaterra Lays out Pipeline Plans Following iStent inject OK, Reacts to CyPass Recall

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 193″]

Chris Calcaterra, COO of Glaukos, revisits the company’s recent good fortune at the FDA, which approved its second generation iStent inject. What’s next for Glaukos? Calcaterra walks OIS Podcast listeners through the company’s “Five in Five” pipeline. In a follow up to the interview, Calcaterra also reacts to Alcon’s decision to recall CyPass. How will this impact Glaukos? Does he have any concerns?